

Winter 2010

In This Issue

American Society of Hematology, ASCO Breast Cancer Symposium, International Society of Pediatric Oncology, International Society for Quality of Life Research, Radiological Society of North America, San Antonio Breast Cancer Symposium, and Others

Cooperative Group Abstracts:

[Breast Cancer](#)
[CNS Cancer](#)
[Gastrointestinal Cancer](#)
[Genitourinary Cancer](#)
[Gynecologic Cancer](#)
[Head and Neck Cancer](#)
[Leukemia,](#)
[Myelodysplasia, and Transplantation](#)
[Lung Cancer](#)
[Lymphoma and Plasma Cell Disorders](#)
[Sarcoma/Bone and Soft Tissue Cancers](#)
[Other Cancer](#)

NCI/CTEP Abstracts & Activities:

[DCTD/DCP Abstracts](#)



The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in July (post AMI, AACR, ACRIN, ASCO and SNM) and in January (post ASCO Breast Symposium, ASH, ASTRO, ISOQOL, RSNA, SABCS, SGO and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.

Research Highlights in this Issue:

CALGB-100104: A randomized phase III trial testing the role of lenalidomide following autologous transplantation for multiple myeloma, was closed early after interim analysis showed that lenalidomide resulted in a 58% reduced risk of progression compared to placebo. This is the first randomized trial to show benefit of maintenance therapy following transplantation for myeloma.

E1199: Evaluated the effect of black race on outcomes by hormone receptor (HR) and HER2 expression in patients treated with standard adjuvant therapy. Observation was made of significant inferior disease-free survival (DFS) and overall survival in black subjects who received chemohormonal therapy with HR+ disease (adjusted for other prognostic factors and BMI) but not in other phenotypes ("triple negative" [TN] or HER-2 pos). This observation suggests that factors other than disparities in care or more advanced or aggressive disease may have contributed to recurrence.

N9831: DFS is significantly improved with the addition of 52 weeks of trastuzumab (H) (sequentially or concurrently) to doxorubicin and cyclophosphamide then paclitaxel (AC→T). There is a statistically significant 33% reduction in the risk of an event with the sequential addition of H following AC→T. There is a strong trend for a 25% reduction in the risk of an event with starting H concurrently with T (AC→T+H→H) relative to sequentially after T (AC→T→H). Therefore, based on a positive risk/benefit ratio, it is recommended that trastuzumab be incorporated in a concurrent fashion with T chemotherapy.



Cooperative Group Abstracts

Breast Cancer

ACRIN

Berg W, Zhang Z, Cormack J, Jong R, Barr R, Lehrer D, et al: Supplemental Yield and Performance Characteristics of Screening MRI after Combined Ultrasound and Mammography: ACRIN 6666. Radiological Society of North America (RSNA), Chicago, IL, Nov, 2009. Abst. VB31-12.

http://rsna2009.rsna.org/search/event_display.cfm?am_id=2&em_id=8002965&printmode=Y&autoprint=N

Protocol(s): ACRIN-6666

Berg W, Zhang Z, Cormack J, Lehrer D, Böhm-Vélez M, Pisano E, et al.: Screening Breast Ultrasound as a Supplement to Mammography: Yield of Annual Screening in ACRIN 6666. Radiological Society of North America (RSNA), Chicago, IL, Nov, 2009. Abst. VB31-04.

http://rsna2009.rsna.org/search/event_display.cfm?am_id=2&em_id=8002537&printmode=Y&autoprint=N

Protocol(s): ACRIN-6666

Berg W, Zhang Z, Marques H, Lehrer D, Böhm-Vélez M, Pisano E, et al.: False Positives Induced by Annual Screening US Added to Mammography: ACRIN 6666. Radiological Society of North America (RSNA), Chicago, IL, Nov, 2009. Abst. VB31-10.

http://rsna2009.rsna.org/search/event_display.cfm?am_id=2&em_id=8003363&printmode=Y&autoprint=N

Protocol(s): ACRIN-6666

Lee J, Kalnins A, Pisano E, Gatsonis C, McMahon P, Kong CY, et al.: Comparative Effectiveness and Cost-Effectiveness of Digital Mammography and MRI for Breast Cancer Screening in BRCA1 Gene Mutation Carriers. Radiological Society of North America (RSNA), Chicago, IL, Nov, 2009. Abst. SSG09-07.

http://rsna2009.rsna.org/search/event_display.cfm?em_id=8002151&printmode=Y&autoprint=N

Protocol(s): ACRIN-6652

Lehman C: Comparison of MRI and Mammography for Evaluation of Residual Disease Following Neoadjuvant Chemotherapy for Locally-Advanced Breast Cancer (ACRIN 6657). American College of Radiology Imaging Network (ACRIN) Fall, Arlington, VA, Sep, 2009.

<http://www.acrin.org/Portals/0/Administration/Communications/2009%20ACRIN%20Fall%20Meeting%20Book.pdf>

Protocol(s): ACRIN-6657

Lehman C, Marques H, Bernreuter W, Pisano E, Rosen M, Hylton N: Assessing Residual Disease in Breast Cancer Patients Post Neoadjuvant Chemotherapy prior to Surgery: Findings of the American College of Radiology Imaging Network (ACRIN) Trial 6657. Radiological Society of North America (RSNA), Chicago, IL, Nov, 2009. Abst. SSJ01-06.

http://rsna2009.rsna.org/search/event_display.cfm?em_id=8009188&printmode=Y&autoprint=N

Protocol(s): ACRIN-6657

CALGB

Berry DA, Thor AD, Jewell SD, Broadwater G, Edgerton SM, Hayes DF, Hudis CA, Winer EP, Nielsen TO, Ellis MJ: Benefits of Adding Paclitaxel to Adjuvant Doxorubicin/Cyclophosphamide Depending on HER2 & ER Status: Analysis of Tumor Tissue Microarrays and Immunohistochemistry in CALGB 9344 (Intergroup 0148). San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 606.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_858

Protocol(s): INT-0148

Other Participating Group(s): ECOG, NCCTG, SWOG

Harris LN, Parker J, Broadwater G, Schulz V, Halligan K, Geyda K, Seidman A, Berry D, Winer E, Hudis C, Krasnitz A, Hicks J, Tuck DP, Perou C: Genome-Wide Profiling of Archived Material from CALGB 9840 and 9342 for Paclitaxel (P) and Trastuzumab (T) Response Biomarkers Using Gene Expression and Copy Number Analysis. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 4032.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_1319

Protocol(s): CALGB-9342, CALGB-9840

Kornblith AB, Archer L, Lan L, Kimmick G, Partridge A, Casey R, Bennett S, Hudis C, Winer E, Cohen HJ, Muss HB: Quality of Life of Early Stage Breast Cancer Patients 65 Years Old or Older Randomized to Standard Chemotherapy or Capecitabine: A Cancer and Leukemia Group B Study (CALGB 49907). San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 5035.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_133

Protocol(s): CALGB-49907

Nielsen TO, Jewell SD, Thor AD, Gao D, Perou CM, Broadwater G, Harris LN, Hayes DF, Berry DA, Ellis MJ: Intrinsic Subtype and Response to Paclitaxel in CALGB 9344 Tissue Microarrays. ASCO Breast Cancer Symposium, San Francisco, CA, Oct, 2009. Abst. 23.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=70&abstractID=40158

Protocol(s): INT-0148

Other Participating Group(s): ECOG, NCCTG, SWOG

Parker JS, Prat A, Cheang MCU, Lenburg ME, Paik S, Perou CM: Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 2019.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_288

Protocol(s): CALGB-150007

Rosen M, Marques H, Herman B, Mies C, DiMichele A, Partridge S, Lehman C, Gatsonis C, Esserman L, Hylton N: Magnetic Resonance Imaging Morphologic Features of Advanced Breast Cancer Predict Surgical and Pathologic Outcomes after Neoadjuvant Chemotherapy. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 4016.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_366

Protocol(s): CALGB-150007

ECOG

Sparano JA, Gray R, Goldstein LJ, Childs BH, Brassard D, Bugarini R, Rowley S, Baker J, Shak S, Badve S, Baehner FL, Kenny P, Perez EA, Shulman LN, Martino S, Sledge GW, Davidson NE: Gene Expression Profiling of Phenotypically-Defined Hormone-Receptor Positive Breast Cancer: Evidence for Increased Transcriptional Activity of the Insulin Growth Factor Receptor Pathway and Other Pathways. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 5165.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_2181

Protocol(s): E2197

Other Participating Group(s): CALGB, NCCTG, SWOG

Sparano JA, Wang W, Stearns V, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson N: Black Race Is Associated with a Worse Outcome in Patients with Hormone Receptor Positive, HER2-Normal Breast Cancer Treated with Adjuvant Chemohormonal Therapy. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 37.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_2025

Protocol(s): E1199

Other Participating Group(s): CALGB, NCCTG, SWOG

Swaby RF, Wang M, Sparano JA, Meropol NJ, Falkson CI, Pellegrino CM, Klein P, Sledge GW: A Phase II Study of the Histone Deacetylase Inhibitor, Vorinostat, in Combination with Trastuzumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent HER-2 Amplified Breast Cancer Resistant to Trastuzumab-Containing Therapy: (E1104) a Trial of the Eastern Cooperative Oncology Group. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 5084.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_816

Protocol(s): E1104

NCCTG

Halyard MY, Pisansky TM, Pierce L, Solin LJ, Perez EA: Changes in Left Ventricular Function after Radiation Therapy and Trastuzumab: Analysis of North Central Cancer Treatment Group Phase III Trial N9831. Int J Radiat Oncol Biol Phys 2009; 75(3, Supplement):Abst. 106.

[http://www.redjournal.org/article/S0360-3016\(09\)01178-X/fulltext](http://www.redjournal.org/article/S0360-3016(09)01178-X/fulltext)

Protocol(s): N9831

Other Participating Group(s): CALGB, ECOG, NCIC Clinical Trials Group, SWOG

Hines SL, Sloan JA, Atherton PJ, Perez EA, Dakhil SR, Johnson DB, Reddy PS, Dalton RJ, Mattar BI, Loprinzi CL: Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women with Primary Breast Cancer (BC) Undergoing Adjuvant Aromatase Inhibitor (AI) Therapy. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 2103.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_1209&terms=

Protocol(s): N02C1

Miller RC, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Atherton PJ, Loprinzi CL, Burger KN, Martenson JA Jr: Comparison of Provider Assessed and Patient Reported Outcome Measures of Acute Skin Toxicity during a Phase III Trial of Mometasone Cream versus Placebo during Breast RT from the North Central Cancer Treatment Group (N06C4). *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 2010.

[http://www.redjournal.org/article/S0360-3016\(09\)01434-5/fulltext](http://www.redjournal.org/article/S0360-3016(09)01434-5/fulltext)

Protocol(s): N06C4

Moreno-Aspitia A, Dueck AC, Patel T, Hillman D, Tenner K, Dakhil SR, Rowland K, McLaughlin SA, Perez EA: Paclitaxel-Related Peripheral Neuropathy Associated with Improved Outcome of Patients with Early Stage HER2+ Breast Cancer Who Did Not Receive Trastuzumab in the N9831 Clinical Trial. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 2100.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_2033&terms=

Protocol(s): N9831

Perez EA, Suman VJ, Davidson NE, Gralow J, Kaufman PA, Ingle JN, Dakhil SR, Zujewski JA, Pisansky TM, Jenkins RB: Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 80.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_992332&terms=

Protocol(s): N9831

Other Participating Group(s): CALGB, ECOG, NCIC Clinical Trials Group, SWOG

Reinholz MM, Kitzmann K, Tenner KS, Hillman DW, Hobday TJ, Roy V, Moreno-Aspitia A, Northfelt DW, Allred JB, LaPlant B, Dueck A, Perez EA, Lingle WL: Circulating Tumor Cells in North Central Cancer Treatment Group Breast Clinical Trials. International Symposium on Minimal Residual Cancer, Athens, Greece, Sep, 2009. Abst. O23.

<http://www.ismrc2009.org/index1.html>

Protocol(s): N0234, N0436, N0338, N0437, N0336

Reinholz MM, Kitzmann KA, Tenner KS, Hillman DW, Hobday T, Roy V, Moreno-Aspitia A, Northfelt D, Allred J, LaPlant B, Dueck AC, Perez EA, and Lingle WL: Circulating Tumor Cells in North Central Cancer Treatment Group Breast Clinical Trials. NCI - Circulating Tumor Cells (CTCs): Emerging Technologies for Detection, Diagnosis and Treatment, Bethesda, MD, Sep, 2009.

Protocol(s): N0437, N0436, N0336, N0234

NCIC Clinical Trials Group

Goss PE, Ingle JN, Martino S, Robert N, Muss H, Shepherd L, Pritchard KI, Livingston RB, Davidson N, Perez EA, Cameron D, Whelan T, Palmer M, Tu D: Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 13.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_801&terms=

Protocol(s): JMA17

Other Participating Group(s): CALGB, ECOG, NCCTG, SWOG

Goss PE, Mamounas EP, Jakesz R, Markopoulos C, Dowsett M, Peto R, Godwin J, Davies C: Aromatase Inhibitors (AIs) Versus Not (Placebo/Observation) as Late Extended Adjuvant Therapy for Postmenopausal Women with Early Stage Breast Cancer (BC): Overviews of Randomized Trials of AIs after ~ 5 Years of Tamoxifen. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 4081.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_701&terms=

Protocol(s): JMA17

Other Participating Group(s): CALGB, ECOG, NCCTG, SWOG

Ingle J, Schaid D, Goss P, Mushiroda T, Chapman J-A, Kubo M, Jenkins G, Batzler A, Liu M, Shepherd L, Ellis M, Flockhart D, Nakamura Y, Weinshilboum R: A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer Entered on NCIC CTG Trial MA.27. A Pharmacogenetics Research Network-RIKEN Collaboration. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 15.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_1950&terms=

Protocol(s): NCIC-MA.27

Stearns V, Chapman J-A, Ma C, Ellis MJ, Ingle J, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maître A, Elliott C, Shepherd L, Goss P: Treatment-Emergent Symptoms and the Risk of Breast Cancer Recurrence in the NCIC CTG MA.27 Adjuvant Aromatase Inhibitor Trial. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 14.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_752&terms=

Protocol(s): NCIC-MA.27

NSABP

Ganz PA: Quality of Life Issues and Outcomes Research in Ductal Carcinoma in Situ. NIH State-of-the-Science Conference: Diagnosis and Management of Ductal Carcinoma In Situ (DCIS), Bethesda, MD, Sep, 2009.

<http://consensus.nih.gov/2009/dcisabstracts.htm>

Protocol(s): NSABP-B-35

Julian TB: Sentinel Lymph Node Biopsy and Management of the Axilla. NIH State-of-the-Science Conference: Diagnosis and Management of Ductal Carcinoma In Situ (DCIS), Bethesda, MD, Sep, 2009.

<http://consensus.nih.gov/2009/dcisabstracts.htm>

Protocol(s): NSABP-B-39, NSABP-B-43

Julian TB, Anderson SJ, Golesorkhi N, Fourchette V, Zheng P, Mamounas EP, Brown AM, Boudros E, Bear HD, Costantino JP, Wolmark N: Predictive Factors for Positive Non-Sentinel Nodes Following a Positive Sentinel Node Biopsy: NSABP B-32. , San Antonio, TX, Dec, 2009. Abst. 301.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_1835

Protocol(s): NSABP-B-32

Swain S: The Impact of Systemic Therapy on Ductal Carcinoma in Situ Outcomes. NIH State-of-the-Science Conference: Diagnosis and Management of Ductal Carcinoma In Situ (DCIS), Bethesda, MD, Sep, 2009.

<http://consensus.nih.gov/2009/dcisabstracts.htm>

Protocol(s): NSABP-B-24

SWOG

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh I-T, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF: Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100). San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 112.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_992333&terms=

Protocol(s): INT-0100

Other Participating Group(s): CALGB, ECOG, NCCTG, NCIC Clinical Trials Group

Sucheston L, Zhao H, Qao S, Budd GT, Barlow WE, Hershman DL, Davis W, Ciupak G, Stewart J, Isaacs C, Hobday T, Latreille J, Hortobagyi GN, Gralow J, Livingston R, Albain K, Hayes DF, Ambrosone CB: Variants in the BRCA1/Fanconi-Anemia Repair Pathway and Taxane-Induced Neuropathy in SWOG S0221. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 2001.

http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_473&terms=

Protocol(s): S0221

CNS Cancer

COG

Donahue B, Marymont M, Kessel S, Landoli MK, FitzGerald TJ, Holmes E, Zhou T, Gajjar A, Packer R: Secondary Radiation Therapy Quality Analysis CCG/POG Intergroup 9961: Implications for Craniospinal Irradiation (CSI). Paediatric Radiation Oncology Society (PROS) Congress, Montreal, Quebec, Canada, Jul, 2009. Abst. FP26.

<http://www.intpros.org/congress/pdf/PROS-abstract.pdf>

Protocol(s): A9961

London WB, Sondel P, Gilman AL, Ozkaynak F, Kreissman S, Buxton A, Chen AR, Matthay KK, Cohn S, Maris JM, Yu A: Success of Chimeric Anti-GD2 Antibody +GM-CSF+IL2 Immunotherapy in High-risk Neuroblastoma (NB) in First Response: a Critical appraisal. *Pediatr Blood Cancer* 2009; 53(5): Abst. S.028.

<http://www3.interscience.wiley.com/journal/122588312/abstract>

Protocol(s): ANBL0032

NCCTG

Jaeckle KA, Brown PD, Buckner JC: Does Survival of Newly Diagnosed GBM Patients Vary as a Function of the Reason for Withdrawal From Active Treatment? An NCCTG Database Study. Joint Meeting of the Society of Neuro-Oncology & AANS/CNS Section on Tumors, New Orleans, LA, Oct, 2009.

Protocol(s): Multiple Trials

Sarkaria JN, Galanis E, Peller PJ, Brown PD, Wu W, Felten SJ, Uhm JH, Giannini C, Jaeckle KA, Buckner JC: Phase I Trial of Everolimus (RAD001) and Temozolomide (TMZ) in Combination with Radiation Therapy (RT) in Newly Diagnosed Glioblastoma Multiforme (GBM) Patients. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, Boston, MA, Nov, 2009. Abst. C56.

http://mct.aacrjournals.org/cgi/content/meeting_abstract/8/12_MeetingAbstracts/C56?sid=7d1823a4-4f94-4e7b-8fbb-790ceb7a4660
Protocol(s): N057K

Gastrointestinal Cancer

ACRIN

Dodd III, GD: Preliminary Results of ACRIN 6673: Multicenter Feasibility Study of Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in Cirrhotic Patients. American College of Radiology Imaging Network (ACRIN) Fall Meeting, Arlington, VA, Sep, 2009.

<http://www.acrin.org/Portals/0/Administration/Communications/2009%20ACRIN%20Fall%20Meeting%20Book.pdf>

Protocol(s): ACRIN-6673

Fidler J: CTC Detection of Flat Adenomas in the National CTC Colonography Trial (ACRIN 6664). American College of Radiology Imaging Network (ACRIN) Fall Meeting, Arlington, VA, Sep, 2009.

<http://www.acrin.org/Portals/0/Administration/Communications/2009%20ACRIN%20Fall%20Meeting%20Book.pdf>

Protocol(s): ACRIN-6664

Fidler J, Zhang Z, Herman B, Limburg P, Fletcher J, Dachman A, et al.: Sensitivity of CT Colonography for the Detection of Nonpolypoid Adenomas Using Restricted Criteria in the ACRIN 6664 National CT Colonography Trial. Radiological Society of North America (RSNA), Chicago, IL, Nov, 2009. Abst. SSA08-07.

http://rsna2009.rsna.org/search/event_display.cfm?em_id=8006962&printmode=Y&autoprint=N

Protocol(s): ACRIN-6664

Siewert B, Gareen I, Vanness D, Herman B, Johnson CD, Gatsonis C: Patient Acceptance and Tolerance of CT Colonography versus Optical Colonoscopy during the National ACRIN CT Colonography Trial. Radiological Society of North America (RSNA), Chicago, IL, Nov, 2009. Abst. SSA08-02.

http://rsna2009.rsna.org/search/event_display.cfm?em_id=8006966&printmode=Y&autoprint=N

Protocol(s): ACRIN-6664

NSABP

Pogue-Geile KL, Fumagalli D, Gavin PG, Colangelo L, Taniyama Y, Kim SI, Choi JH, Kim C, Kuebler JP, Geyer CE Jr, Petrelli N, O'Connell MJ, Yothers G, Paik S, Wolmark N: Mutation Profiling and Prognostic Value of BRAF, HRAS, KRAS, MET, NRAS, PIK3CA, KRASG12V in Colon Cancer: Results from NSABP C-07. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, Boston, MA, Nov, 2009. Abst. A201.

http://mct.aacrjournals.org/cgi/content/meeting_abstract/8/12/MeetingAbstracts/A201?sid=7c3c5ddd-3ad1-42ed-aaae-524b51f68f1d

Protocol(s): NSABP-C-07

RTOG

Ben-Josef E, Moughan J, Ajani J, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal S, Willett C: The Impact of Overall Treatment Time on Survival and Local Control in Anal Cancer Patients: A Pooled Data Analysis of RTOG Trials 8704 and 9811. Int J Radiat Oncol Biol Phys 2009; 75(3, Supplement): Abst. 55.

[http://www.redjournal.org/article/S0360-3016\(09\)01126-2/fulltext#sec2](http://www.redjournal.org/article/S0360-3016(09)01126-2/fulltext#sec2)

Protocol(s): RTOG-87-04, RTOG-98-11

Other Participating Group(s): CALGB, ECOG, NCCTG, NCIC Clinical Trials Group, SWOG

Kachnic L, Winter K, Myerson R, Goodyear M, Willins J, Esthappen J, Haddock M, Rotman M, Parikh P, Willett C. RTOG 0529: A Phase II Evaluation of Dose-Painted IMRT in Combination with 5-Fluorouracil and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal. Int J Radiat Oncol Biol Phys 2009; 75(3, Supplement): Abst. 10.

[http://www.redjournal.org/article/S0360-3016\(09\)01080-3/fulltext](http://www.redjournal.org/article/S0360-3016(09)01080-3/fulltext)

Protocol(s): RTOG-0529

Regine W, Winter K, Abrams R, Safran H, Hoffman J, Konski A, Benson III A, MacDonald J, Willett C, Rich T. Five-year Results of the Phase III Intergroup Trial (RTOG 97-04) of Adjuvant Pre and Post Chemoradiation (CRT) 5-FU vs. Gemcitabine (G) for Resected Pancreatic Adenocarcinoma: Implications for Future International Trial Design. Int J Radiat Oncol Biol Phys 2009; 75(3, Supplement): Abst. 117.

[http://www.redjournal.org/article/S0360-3016\(09\)01189-4/fulltext](http://www.redjournal.org/article/S0360-3016(09)01189-4/fulltext)

Protocol(s): RTOG-97-04

Other Participating Group(s): ECOG, SWOG

SWOG

Thomas CR, Goldman BH, Benedetti JK, Lenz HJ, Baker TA, Hammond-Thelin L, Mehta VK, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD: Cetuximab (C225) Plus Cisplatin (CDDP) Irinotecan (CPT11) and Thoracic Radiotherapy (TRT) Definitive Treatment for Locally-advanced, Clinically Unresectable Esophageal Cancer: A Southwest Oncology Group (SWOG) Phase II Trial with Molecular Correlates (S0414). Int J Radiat Oncol Biol Phys 2009; 75(3, Supplement): Abst. 1094.

[http://www.redjournal.org/article/S0360-3016\(09\)01434-5/fulltext](http://www.redjournal.org/article/S0360-3016(09)01434-5/fulltext)

Protocol(s): S0414

Genitourinary Cancer

RTOG

Du K, Bae K, Movsas B, Gamerman V, Coyne J, Bryan C, Watkins-Bruner D. The Impact of Marital Status and Race in Patients Enrolled in Radiation Therapy Oncology Group (RTOG) Prostate Cancer Trials. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 1016.

[http://www.redjournal.org/article/S0360-3016\(09\)01355-8/fulltext](http://www.redjournal.org/article/S0360-3016(09)01355-8/fulltext)

Protocol(s): RTOG-92-02, RTOG-94-03

Lawton C, Hunt D, Lee W, Gomella L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H. Long Term Results of a Phase II Trial of Ultrasound-Guided Radioactive Implantation of the Prostate for Definitive Management of Localized Adenocarcinoma of the Prostate (RTOG 98-05). *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 25.

[http://www.redjournal.org/article/S0360-3016\(09\)01095-5/fulltext](http://www.redjournal.org/article/S0360-3016(09)01095-5/fulltext)

Protocol(s): RTOG-98-05

McGowan D, Hunt D, Jones C, Amin M, Leibenhaut M, Husian S, Rotman M, Souhami L, Sandler H, Shipley W. Short-term endocrine therapy prior to and during radiation therapy improves overall survival in patients with T1b-T2b adenocarcinoma of the prostate and PSA \leq 20: Initial results of RTOG 94-08. American Society of Radiation Oncology (ASTRO) Annual Meeting, Chicago, IL, Nov, 2009. Late-breaking abstract.

Protocol(s): RTOG-94-08

Zietman A, Bae K, Rossi C, Slater J, Efstathiou J, Coen J, Lunt M, Spiegel D, Skowronski R, Shipley W. A Phase III Trial Employing Conformal Photons with Proton Boost in Early Stage Prostate Cancer: Conventional Dose (70.2GyE) Compared to High Dose Irradiation (79.2 GyE): Long-term Updated Analysis of Proton Radiation Oncology Group (PROG)/American College Of Radiology (ACR) 95-09. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 22.

[http://www.redjournal.org/article/S0360-3016\(09\)01092-X/fulltext](http://www.redjournal.org/article/S0360-3016(09)01092-X/fulltext)

Protocol(s): PROG-95-09

Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H. Impact of Ultrahigh Baseline PSA Levels on Biochemical and Clinical Outcomes in Two Radiation Therapy Oncology Group (RTOG) Prostate Clinical Trials. Canadian Association of Radiation Oncology Annual Scientific Meeting, Quebec City, Quebec, Canada, Sept, 2009.

http://www.caro-acro.ca/Meetings_Education/Annual_Scientific_Meetings/23rd_Annual_Scientific_Meeting_September_30_-_October_3_2009_Quebec_City.htm

Protocol(s): RTOG-92-02, RTOG-94-13

SWOG

Goodman PJ, Hartline J, Lippman SM, Klein EA: Moving to centralized follow-up from a site-based model in a large cancer prevention study. *Frontiers in Cancer Prevention Research*, Houston, TX, Dec, 2009. Abst. A85.

http://www.aacr.org/Uploads/DocumentRepository/2009_conf/CPR/cpr09_abstracts_poster_a.pdf

Protocol(s): Multiple Trials

Lerner, SP: P53 and Other Biomarkers. World Urologic Oncology Federation Meeting, Shanghai, China, Nov, 2009.

Protocol(s): SWOG-4B951

Swanson GP, Goldman BH, Tangen C, Thompson IM, Chin J, Messing E, Canby-Higano E, Foreman JD, Crawford ED: Lack of Low-risk Pathologic Findings in SWOG 8794. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 20.

[http://www.redjournal.org/article/S0360-3016\(09\)01090-6/fulltext](http://www.redjournal.org/article/S0360-3016(09)01090-6/fulltext)

Protocol(s): INT-0086

Other Participating Group(s): CALGB, ECOG, NCCTG, NCIC Clinical Trials Group, RTOG

Gynecologic Cancer

RTOG

Doll C, Winter K, Gaffney D, Ryu J, Jhingran A, Dicker A, Weidhaas J, Miller B, Magliocco A. Low COX-2 Expression, But Not CD34, Predicts for Worse Overall Survival in Patients with Locally-advanced Cervical Cancer Treated with Chemoradiotherapy and Celecoxib: A Comparative Immunohistochemical Analysis of RTOG 0128. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 1057.

[http://www.redjournal.org/article/S0360-3016\(09\)01397-2/fulltext](http://www.redjournal.org/article/S0360-3016(09)01397-2/fulltext)

Protocol(s): RTOG-C-0128

Fyles A, Lim K, Small Jr W, Portelance L, Gaffney D, Erickson B, de los Santos J, Ishikura S, Creutzberg C, Bosch W. Variability in Delineation of Clinical Target Volumes for Cervix Cancer Intensity-modulated Pelvic Radiotherapy. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 177.

[http://www.redjournal.org/article/S0360-3016\(09\)01250-4/fulltext](http://www.redjournal.org/article/S0360-3016(09)01250-4/fulltext)

Protocol(s): Multiple Trials

Portelance L, Winter K, Jhingran A, Miller B, Salehpour M, D'Souza D, Haddock M, Rotman M, Gaffney D. Post-operative Pelvic Intensity Modulated Radiation Therapy (IMRT) with Chemotherapy for Patients with Cervical Carcinoma / RTOG 0418 Phase II study. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 3022.

[http://www.redjournal.org/article/S0360-3016\(09\)02504-8/fulltext](http://www.redjournal.org/article/S0360-3016(09)02504-8/fulltext)

Protocol(s): RTOG-0418

Viswanathan A, Moughan J, Small W, Levenback C, Iyer R, Hymes S, Dicker A, Miller B, Erickson B, Gaffney D. Quality Of Cervical Cancer Brachytherapy Implantation In RTOG Prospective Trials. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 183.

[http://www.redjournal.org/article/S0360-3016\(09\)01256-5/fulltext](http://www.redjournal.org/article/S0360-3016(09)01256-5/fulltext)

Protocol(s): RTOG-0116, RTOG-C-0128

Head and Neck Cancer

ECOG

Quon H, Lee J, Langer CJ, Patel UA, Shin DM, Argiris A, Ridge JA, Burtress BA, Forastiere AA: E3303: A Phase II Study of Cetuximab (C225) in Combination with Cisplatin (DDP) and Definitive Radiation (XRT) in Unresectable Squamous Cell Carcinoma of the Head and Neck (U-SCCHN). *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 30.

[http://www.redjournal.org/article/S0360-3016\(09\)01100-6/fulltext](http://www.redjournal.org/article/S0360-3016(09)01100-6/fulltext)

Protocol(s): E3303

RTOG

Ang K, Pajak T, Wheeler R, Rosenthal D, Nguyen F, Lu C, Kim H, Axelrod R, Silverman C, Weber R. A phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas (RTOG0129): Report of efficacy and toxicity. American Society of Radiation Oncology (ASTRO) Annual Meeting, Chicago, IL, Nov, 2009. Late-breaking abstract.

Protocol(s): RTOG-0129

Kies M, Harris J, Rotman M, Myers J, Foote R, Machtay M, Khuntia D, Straube W, Ang K, Harari P. Phase II randomized trial of postoperative chemoradiotherapy plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234). *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 29.

[http://www.redjournal.org/article/S0360-3016\(09\)01099-2/fulltext](http://www.redjournal.org/article/S0360-3016(09)01099-2/fulltext)

Protocol(s): RTOG-0234

Leukemia, Myelodysplasia, and Transplantation

CALGB

Attar EC, Maharry K, Mrózek K, Radmacher MD, Whitman SP, Paschka P, Langer C, Holland KB, Powell BL, Kolitz JE, Carroll AJ, Larson RA, Marcucci G, Bloomfield CD: Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study. *Blood* 2009; 114(22): Abst. 1616.

<http://ash.confex.com/ash/2009/webprogram/Paper22984.html>

Protocol(s): CALGB-9665, CALGB-20202, CALGB-8461

Farag S, Owzar K, Hars V, Lazarus HM, Stadtmauer EA, Devine SM, van Besien K, Linker C: A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study. *Blood* 2009; 114(22): Abst. 2238.

<http://ash.confex.com/ash/2009/webprogram/Paper22952.html>

Protocol(s): CALGB-100101

Other Participating Group(s): ECOG

Lin TS, Donohue KA, Byrd JC, Lucas MS, Hoke E, Bengtson EM, Atkins JN, Link BK, Rai KR, Larson RA: Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101. *Blood* 2009; 114(22): Abst. 210.

<http://ash.confex.com/ash/2009/webprogram/Paper20988.html>

Protocol(s): CALGB-10101

Mrózek K, Holland KB, Pettenati MJ, Maharry K, Marcucci G, Baer MR, Kolitz JE, Margeson D, Edwards CG, Carroll AJ, Larson RA, Bloomfield CD: Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define “Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes” in Adults: a Cancer and Leukemia Group B (CALGB) Study. *Blood* 2009; 114(22): Abst. 2602.

<http://ash.confex.com/ash/2009/webprogram/Paper18621.html>

Protocol(s): CALGB-8461

Rai KR, Peterson BL, Appelbaum FR, Tallman MS, Belch A, Morrison VA, Larson RA: Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL). *Blood* 2009; 114(22): Abst. 536.

<http://ash.confex.com/ash/2009/webprogram/Paper20588.html>

Protocol(s): CALGB-9011

Other Participating Group(s): ECOG, NCIC Clinical Trials Group, SWOG

Stock W, Sanford B, Lozanski G, Vij R, Byrd JC, Powell BL, Wetzler M, Sher D, Edwards C, Kelly M, Richards S, Sung C, Malnassy G, Hoke E, Bloomfield CD, Larson RA: Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102). *Blood* 2009; 114(22): Abst. 838.

<http://ash.confex.com/ash/2009/webprogram/Paper19787.html>

Protocol(s): CALGB-10102

Whitman SP, Maharry K, Radmacher MD, Mrózek K, Margeson D, Holland KB, Becker H, Wu YZ, Schwind S, Baer MR, Powell BL, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD: Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [=60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study. *Blood* 2009; 114(22): Abst. 1579.

<http://ash.confex.com/ash/2009/webprogram/Paper18591.html>

Protocol(s): CALGB-9720, CALGB-10201, CALGB-8923, CALGB-8525, CALGB-9420

Woyach JA, Ruppert AS, Heerema NA, Peterson B, Gribben JG, Morrison VA, Rai KR, Larson RA, Byrd JC: Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712. *Blood* 2009; 114(22): Abst. 539.

<http://ash.confex.com/ash/2009/webprogram/Paper21022.html>

Protocol(s): CALGB-9712

COG

Araten DJ, Sanders K, Anscher D, Hunger S, Ibrahim S: A high frequency of blasts with the PNH phenotype in patients with ALL. *Blood* 2009; 114(22): Abst. 1575.

<http://ash.confex.com/ash/2009/webprogram/Paper18051.html>

Protocol(s): AALL05B1

Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo T, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson BE, Hasle H, Harrison CJ, Heerema NA, Kaspers GL, Lezl A, Litvinko N, Nigro LL, Morimoto A, Perot C, et al.: Identification of Novel Prognostic Subgroups in Childhood 11Q23/MLL-Rearranged Acute Myeloid Leukemia. *Pediatr Blood Cancer* 2009; 53(5): Abst. O.034.

<http://www3.interscience.wiley.com/journal/122588312/abstract>

Protocol(s): CCG-2941, CCG-2961, CCG-2891

Berman JN, Gerbing R, Sung L, Miller K, Pollard JA, Ho PA, Stirewalt DL, Radich JP, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Gamis A, Franklin J, Alonzo T, Meshinchi S: Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML: A Report From the Children's Oncology Group. *Blood* 2009; 114(22): Abst. 3115.

<http://ash.confex.com/ash/2009/webprogram/Paper20420.html>

Protocol(s): CCG-2961, AAML03P1

Brown P, Hilden JM, Dreyer Z, Winick N, Salzer WL, Sung L, Zaoutis T, Jones T, Devidas M, de Lorenzo P, Valsecchi MG, Pieters R, Carroll WL, Hunger S: Report on excessive induction toxicity in infants with ALL enrolled on COG protocol AALL0631: A Children's Oncology Group study. *Blood* 2009; 114(22): Abst. 3091.

<http://ash.confex.com/ash/2009/webprogram/Paper25304.html>

Protocol(s): AALL06B1

Carroll AJ, Heerema NA, Devidas M, Bowman P, Wang C, Trigg ME, Camitta BM, Gaynon PS, Winick N, Hunger S, Carroll WL, Schultz KR: Secondary Chromosomal Abnormalities Appear to Be Less Prognostic for Children with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with Intensified Imatinib and Chemotherapy: Results of the Children's Oncology Group (COG) Study AALL0031. *Blood* 2009; 114(22): Abst. 2606.

<http://ash.confex.com/ash/2009/webprogram/Paper19180.html>

Protocol(s): AALL0031

Carroll AJ, Heerema NA, Gastier-Foster JM, Astbury C, Pyatt RE, Reshmi SC, Borowitz M, Devidas M, Linda SB, Loh M, Hunger S, Carroll WL: Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study. *Blood* 2009; 114(22): Abst. 1580.

<http://ash.confex.com/ash/2009/webprogram/Paper18636.html>

Protocol(s): AALL03B1

Chang BH, Willis SG, Stork L, Schultz KR, Hunger S, Carroll WL, Camitta BM, Winick N, Drunker BJ: Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group. *Blood* 2009; 114(22): Abst. 2634.

<http://ash.confex.com/ash/2009/webprogram/Paper22289.html>

Protocol(s): AALL0031

Chen L, Devidas M, Waller J, Hall P, Lukacik M, Camitta BM, Bell B: Hepatotoxicity in Standard Risk B-Cell Precursor Pediatric Acute Lymphoblastic Leukemia Patients Treated On Pediatric Oncology Group (POG) Protocol 9605. *Blood* 2009; 114(22): Abst. 2032.

<http://ash.confex.com/ash/2009/webprogram/Paper21051.html>

Protocol(s): POG-9605

Cooper TM, Alonzo T, Gerbing R, Perentesis J, Whitlock JA, Raetz E, Carroll WL, Gamis A, Razzouk B: AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia. *Blood* 2009; 114(22): Abst. 3076.

<http://ash.confex.com/ash/2009/webprogram/Paper24560.html>

Protocol(s): AAML0523

Dhall G, Jones T, Radvinsky D, Robison NJ, Rubin JI, Gaynon PS, Panosyan E, Avramis IA, Butturini AM, Avramis VI, Ettinger LJ, Seibel N: Adverse Reactions to PEG and Erwinia Asparaginase and Correlation with Anti-Asparaginase Antibody Data and Survival in Children with Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group Study CCG 1961. *Blood* 2009; 114(22): Abst. 3077.

<http://ash.confex.com/ash/2009/webprogram/Paper24949.html>

Protocol(s): CCG-1961

Gutierrez A, Grebliunaite R, Dahlberg S, Neuberg D, Zhang J, Sanda T, Protopopov A, Chin L, Winter SS, Larson RS, Kutok J, Silverman LB, Hunger S, Sallan SE, Look AT: Absence of T-Cell Receptor Gene Rearrangements Predicts Induction Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. *Blood* 2009; 114(22): Abst. 910.

<http://ash.confex.com/ash/2009/webprogram/Paper21035.html>

Protocol(s): POG-9404

Haugen MS, Toomey DA, Byron P: Acute Lymphoblastic Leukemia in the Adolescent and Young Adult: An Education Module for Clinical Trial, CALGB 10403. Association of Pediatric Hematology/Oncology Nurses (APHON), Orlando, FL, Sep, 2009.

<http://www.aphon.org/meetings/conference/>

Protocol(s): AALL0232

Heerema NA, Carroll AJ, Borowitz M, Devidas M, Larsen EC, Loh M, Mattano, Jr. LA, Maloney K, Raetz E, Wood BL, Winick N, Hunger S, Carroll WL: Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy: A Report From the Children's Oncology Group (COG). *Blood* 2009; 114(22): Abst. 2598.

<http://ash.confex.com/ash/2009/webprogram/Paper18265.html>

Protocol(s): AALL03B1, AALL0232, AALL0331

Hogan L, Bhojwani D, Wang J, Morrison D, Yang JJ, Zhang Y, Zavadil J, Condos G, Hunger S, Willman CL, Relling MV, Raetz E, Carroll WL: Up-Regulation of Genes Involved in Folate Metabolism Characterize Late but Not Early Relapse in Childhood Acute Lymphoblastic Leukemia. *Blood* 2009; 114(22): Abst. 1733.

<http://ash.confex.com/ash/2009/webprogram/Paper18572.html>

Protocol(s): AALL05B1

Hunger S, Mullighan C, Downing JR, Relling MV, Willman CL, Devidas M, Reaman GH, Carroll WL, Smith M, Zhang J, Gerhard D: The Spectrum of Mutations in Childhood ALL. SIOP 2009 Award Session - Winner of SIOP Award for Basic Science. *Pediatr Blood Cancer* 2009; 53(5): Abst. O.065.

<http://www3.interscience.wiley.com/journal/122588312/abstract>

Protocol(s): POG-9906

Kutny M, Alonzo T, Gerbing R, Miller K, Ho PA, Heerema NA, Lange B, Gamis A, Meshinchi S: RUNX1 Mutations in Pediatric AML: A Report From the Children's Oncology Group. *Blood* 2009; 114(22): Abst. 2614.

<http://ash.confex.com/ash/2009/webprogram/Paper20373.html>

Protocol(s): CCG-2941, CCG-2961

Matloub YH, Bostrom BC, Angiolillo A, Devidas M, Heerema NA, Gastier-Foster JM, Hunger S, Sather H, Linda SB, Carroll WL, Nachman J, Gaynon PS: Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study. *Blood* 2009; 114(22): Abst. 320.

<http://ash.confex.com/ash/2009/webprogram/Paper20261.html>

Protocol(s): CCG-1991

Mullighan C, Collins-Underwood J, Phillips LA, Loudin M, Liu W, Zhang J, Ma J, Coustan-Smith E, Harvey RC, Willman CL, Cheng J, Mikhail F, Meyer J, Williams RT, Carroll AJ, Heerema NA, Basso G, Pession A, Pui C, Raimondi SC, Hunger S, et al.: Rearrangement of CRLF2 in B-Progenitor and Down Syndrome Associated Acute Lymphoblastic Leukemia. *Blood* 2009; 114(22): Abst. 182.

<http://ash.confex.com/ash/2009/webprogram/Paper20601.html>

Protocol(s): AALL05B1

Mullighan C, Morin RD, Zhang J, Hirst M, Zhao Y, Yan CY, Finney R, Edmonson M, Su X, Buetow KE, Carroll WL, Chen I, Devidas M, Gerhard D, Harvey RC, Hu Y, Loh M, Reaman GH, Relling MV, Smith M, Downing JR, Hunger S, Willman CL, Marra MA: Next Generation Transcriptomic Resequencing Identifies Novel Genetic Alterations in High-Risk (HR) Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) HR ALL TARGET Project. *Blood* 2009; 114(22): Abst. 704.

<http://ash.confex.com/ash/2009/webprogram/Paper20583.html>

Protocol(s): POG-9906

Myers K, Gerbing R, Alonzo T, Phillips C, Gamis A, Radloff GA, Perentesis J, Davies SM: Pathway Based Evaluation of Cytarabine Pharmacogenetics in Children with Acute Myeloid Leukemia. *Blood* 2009; 114(22): Abst. 2610.

<http://ash.confex.com/ash/2009/webprogram/Paper19575.html>

Protocol(s): CCG-2941, CCG-2961

O'Brien MM, Dahl G, Pounds S, Lacayo N, Taub J, Chang M, Weinstein H, Ravindranath Y, Campana D, Pui C, Rubnitz JE: Acute Megakaryoblastic Leukemia (AMKL) in Children without Down Syndrome. *Blood* 2009; 114(22): Abst. 482.

<http://ash.confex.com/ash/2009/webprogram/Paper24758.html>

Protocol(s): POG-9421

Rabin K, Wang J, Meyer J, Loudin M, Bhojwani D, Morrison D, Devidas M, Heerema NA, Carroll AJ, Pession A, Basso G, Mullighan C, Hunger S, Carroll WL: Gene Expression Profiling in Down Syndrome Acute Lymphoblastic Leukemia Identifies Distinct Profiles Associated with CRLF2 Expression Status. *Blood* 2009; 114(22): Abst. 2389.

<http://ash.confex.com/ash/2009/webprogram/Paper19836.html>

Protocol(s): POG-9900

Robb SL, Burns DS, Haase JE: Researchers and Clinicians Engaged in SMART Quality Assurance Monitoring. American Music Therapy Association, San Diego, CA, Nov, 2009.

<http://www.musictherapy.org/conference/confindex.html>

Protocol(s): ANUR0631

Robb SL, Docherty S, Haase JE: Ensuring Treatment Fidelity in a Multi-site Behavioral Intervention Study: Implementing NIH Behavior Change Consortium Recommendations in the SMART trial. American Music Therapy Association, San Diego, CA, Nov, 2009.

<http://www.musictherapy.org/conference/confindex.html>

Protocol(s): ANUR0631

Robinson B, Devidas M, Carroll AJ, Heerema NA, Willman CL, Hudome A, Woods EC, Ballantyne N, Reaman GH, Hilden JM, Camitta BM, Winick N, Carroll WL, Hunger S, Dreyer Z, Felix CA: Specific MLL Partner Genes in Infant Acute Lymphoblastic Leukemia (ALL) Associated with Outcome Are Linked to Age and White Blood Cell Count (WBC) at Diagnosis: A Report On the Children's Oncology Group (COG) P9407 Trial. *Blood* 2009; 114(22): Abst. 907.

<http://ash.confex.com/ash/2009/webprogram/Paper20312.html>

Protocol(s): P9407

Stegenga K, Docherty S, Phillips-Salimi C, Donovan M, Hendricks-Ferguson VL, Barnes YJ, Haase JE: Across the Miles: Strategies to Make Collaborative Multi-site Qualitative Research Possible. *International Journal of Qualitative Methods* 2009; 8(4).

<http://ejournals.library.ualberta.ca/index.php/IJQM/article/view/7194/5886>

Protocol(s): ANUR0631

Stegenga K, Robb SL, Burns DS, Haase JE: Synergistic Use of Qualitative and Quantitative Approaches to Inform Behavioral Oncology Interventions. *International Journal of Qualitative Methods* 2009; 8(4).

<http://ejournals.library.ualberta.ca/index.php/IJQM/article/view/7194/5886>

Protocol(s): ANUR0631

Walter R, Alonzo T, Gerbing R, Smith FO, Raimondi SC, Hirsch B, Gamis A, Franklin J, Hurwitz C, Loken MR, Meshinchi S: High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group. *Blood* 2009; 114(22): Abst. 1592.

<http://ash.confex.com/ash/2009/webprogram/Paper20440.html>

Protocol(s): AAML03P1

Wood BL, Winter SS, Dunsmore KP, Raetz E, Borowitz M, Devidas M, Winick N, Carroll WL, Hunger S, Loh M: Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of induction—A Children's Oncology Group (COG) Study. *Blood* 2009; 114(22): Abst. 9.

<http://ash.confex.com/ash/2009/webprogram/Paper25398.html>

Protocol(s): AALL03B1, AALL0434

Zhang J, Mullighan C, Harvey RC, Buetow KE, Carroll WL, Chen I, Devidas M, Edmonson M, Gerhard D, Hu Y, Loh M, Phillips LA, Reaman GH, Relling MV, Smith M, Downing JR, Willman CL, Hunger S: Mutations in the RAS Signaling, B-Cell Development, TP53/RB1, and JAK Signaling Pathways Are Common in High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project. *Blood* 2009; 114(22): Abst. 85.

<http://ash.confex.com/ash/2009/webprogram/Paper23892.html>

Protocol(s): POG-9906

ECOG

Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta EM, Dewald G, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS: Autologous Hematopoietic Cell Transplantation as Consolidation for Younger Patients with Acute Myeloid Leukemia in First Complete Remission: Follow-up of E1900. *Blood* 2009; 114(22): Abst. 3405.

<http://ash.confex.com/ash/2009/webprogram/Paper25009.html>

Protocol(s): E1900

SWOG

Advani A, Gundacker H, Sala-Torra L, Radich J, Lai R, Lancet J, Coutre S, Stuart RK, Mims MP, Stiff P, Appelbaum FR: Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia. *Blood* 2009; 114(22): Abst. 3094.

<http://ash.confex.com/ash/2009/webprogram/Paper18055.html>

Protocol(s): S0530

Petersdorf SH, Kopecky KJ, Stuart RK, Nevill TJ, Larson R, Stenke L, Tallman M, Slovak M, Willman C, Erba H, Appelbaum F: Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia. *Blood* 2009; 114(22): Abst. 790.

<http://ash.confex.com/ash/2009/webprogram/Paper22999.html>

Protocol(s): S0106

Lymphoma and Plasma Cell Disorders

CALGB

McCarthy PL, Owzar K, Stadtmauer EA, Giral S, Hurd DD, Hassoun H, Hofmeister C, Richardson P, Weisdorf DJ, Pasquini MC, Hars V, Kelly M, Postiglione J, Sutherland S, Anderson KC, Linker C: Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events. *Blood* 2009; 114(22): Abst. 3416.

<http://ash.confex.com/ash/2009/webprogram/Paper22181.html>

Protocol(s): CALGB-100104

COG

Cairo M, Lynch J, Harrison L, Perkins S, Sanger W, Gross TG, Shiramizu B, Goldman SC: Results of the Addition of Rasburicase (RU) and Rituximab (RM) to the FAB/LMB 96 Chemotherapy Backbone in Children and Adolescents (C+A) with Mature B-NHL: A Children's Oncology Group Report. *Pediatr Blood Cancer* 2009; 53(5): Abst. PQ.018.

<http://www3.interscience.wiley.com/journal/122588312/abstract>

Protocol(s): ANHL01P1

Goldman SC, Lynch J, Harrison L, Gross TG, Shiramizu B, Sanger W, Perkins S, Cairo M: Preliminary Results of the Addition of Rasburicase to the Reduction Cycle and Rituximab to the Induction and Consolidation Cycles of FAB Group C Chemotherapy in Children and Adolescents with Advanced Stage (Bone Marrow ±CNS) Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report. *Blood* 2009; 114(22): Abst. 104.

<http://ash.confex.com/ash/2009/webprogram/Paper18900.html>

Protocol(s): ANHL01P1

ECOG

Advani RH, Hong F, Ganjoo K, Manola J, Swinnen LJ, Habermann TM, Horning SJ: Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CHOP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial. *Blood* 2009; 114(22): Abst. 1671.

<http://ash.confex.com/ash/2009/webprogram/Paper24530.html>

Protocol(s): E2404

Kahl BS, Li H, Smith MR, Gascoyne RD, Paietta EM, Advani RH, Horning SJ: The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. *Blood* 2009; 114(22): Abst. 1661.

<http://ash.confex.com/ash/2009/webprogram/Paper22830.html>

Protocol(s): E1405

NCCTG

Maurer MJ, Micallef IN, Katzmann JA, Nikcevich DA, Witzig TE: Elevated Pre-Treatment Serum Immunoglobulin Free Light Chains (FLC) Are Associated with Poor Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL). *Blood* 2009; 114(22): Abst. 136.

<http://ash.confex.com/ash/2009/webprogram/Paper18853.html>

Protocol(s): N0489

Micallef IN, Maurer MJ, Witzig TE, Nikcevich D, Kurtin P, Cannon MW, Flynn PJ, Soori GS, Lowe V, Wiseman G: PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. *Blood* 2009; 114(22): Abst. 137.

<http://ash.confex.com/ash/2009/webprogram/Paper17342.html>

Protocol(s): N0489

NCIC Clinical Trials Group

Buckstein R, Kuruvilla J, Chua N, Lee C, Macdonald DA, Al-Tourah AJ, Foo A, Walsh W, Ivy SP, Crump M, Eisenhauer E: Sunitinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: Results of a Phase II Multi-Center Study of the NCIC Clinical Trials Group. *Blood* 2009; 114(22): Abst. 2729.

<http://ash.confex.com/ash/2009/webprogram/Paper23987.html>

Protocol(s): NCIC-182

SWOG

Cardesa T, Colomo L, Climent F, Gonzalez-Barca E, Gutierrez G, Mercadal S, Gascoyne RD, Connors J, Rimsza L, Braziel R, Cook J, Tubbs R, Rosenwald A, Ott G, Mate JL, Ribera JM, Arenillas L, Serrano S, Combalia N, Delabie J, Lenz G, Wright G, et al.: High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT). *Blood* 2009; 114(22): Abst. 1948.

<http://ash.confex.com/ash/2009/webprogram/Paper23924.html>

Protocol(s): SWOG-8819

Deffenbacher D, Iqbal J, Liu Z, Perkins S, Lim M, Fu K, Shen J, Staudt L, Rimsza L, Jaffe E, Rosenwald A, Delabie J, Campo J, Gascoyne R, Weisenberger D, Greiner T, Gross TG, Chan W: Chromosomal Alterations in Gene Expression-Defined Pediatric Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL). *Blood* 2009; 114(22): Abst. 2922.

<http://ash.confex.com/ash/2009/webprogram/Paper19336.html>

Protocol(s): SWOG-8819

Johnson NA, Ben-Neriah S, Savage KJ, Lee T, Horsman DE, Connors JM, Chan WC, Lenz G, Wright G, Rimsza L, Braziel R, Cook J, Tubbs R, Weisenburger D, Campo E, Rosenwald A, Ott G, Delabie J, Jaffe ES, Staudt LM, Gascoyne RD: MYC Translocations and Expression Are Clinically Important in R-CHOP Treated Patients with De Novo DLBCL. *Blood* 2009; 114(22): Abst. 1100.

<http://ash.confex.com/ash/2009/webprogram/Paper22995.html>

Protocol(s): SWOG-8819

Persky D, Bornan D, Goldman B, LeBlanc M, Brazier RM, Fisher RI, Maloney D, Miller T, Press OW, Rimsza LM: Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone. *Blood* 2009; 114(22): Abst. 111.

<http://ash.confex.com/ash/2009/webprogram/Paper18948.html>

Protocol(s): S9911, S9800, SWOG-8809

Rimsza LM, Wright GL, Schwartz M, Chan J, Jaffe E, Gascoyne R, Campo E, Rosenwald A, Ott G, Cook J, Tubbs RR, Brazier R, Delabie J, Miller T, Fisher RI, Staudt L: Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project. *Blood* 2009; 114(22): Abst. 620.

<http://ash.confex.com/ash/2009/webprogram/Paper19788.html>

Protocol(s): SWOG-8819

Lung Cancer

ACRIN

Aberle D: Minority Accrual into the National Lung Screening Trial (ACRIN 6654). American College of Radiology Imaging Network (ACRIN) Fall, Arlington, VA, Sep, 2009.

<http://www.acrin.org/Portals/0/Administration/Communications/2009%20ACRIN%20Fall%20Meeting%20Book.pdf>

Protocol(s): ACRIN-6654

ECOG

Hoang T, Dahlberg SE, Schiller JH, Johnson DH: Does Histology Predict Survival of Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Standard Platin-Based Chemotherapy? Retrospective Analysis of E1594. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. PD6.4.1.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): E1594

NCCTG

Adjei A, Adjei AA, Salavaggione OE, Mandrekar SJ, Dy GK, Allen-Ziegler KA, Endo C, Molina JR, Schild SE: Correlation between polymorphisms in the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in Non-Small Cell Lung Cancer (NSCLC): An NCCTG N0026 Based Study. NCI Translational Science Meeting, Vienna, VA, Nov, 2009. Abst. 198.

<http://ncitranslates.nci.nih.gov/docs/TSM2%20Abstract%20Book%20FINAL.pdf>

Protocol(s): N0026

Molina JR, Adjei AA, Foster NR, Schild SE, Wright J: NCCTG Phase II Trial (N0621) of the SRC Inhibitor AZD0530 after 4 Cycles of Cytoreductive Chemotherapy for Patients with Extensive Stage Small Cell Lung Cancer (ED-SCLC). *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. PD4.3.4.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): N0621

Molina JR, Mandrekar SJ, Allen-Ziegler K, Soori GS, Rowland KM, Schild SE, Ivy P, Adjei AA: A Phase II Study of the VEGFR Inhibitor Pazopanib (P) in Patients with Newly Diagnosed or Relapsed Malignant Pleural Mesothelioma (MPM): An NCCTG study. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. PD4.1.2.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): N0623

Schild SE, Graham DL, Hillman SL, Vora SA, Garces YI, Molina JR, Shahidi H, Kugler JW, Adjei AA: Survival of Patients Treated with High-dose Radiotherapy (RT) & Concurrent Chemotherapy for Unresectable Non-Small Cell Lung Cancer (NSCLC). *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. B5.4.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): N0028

RTOG

Bradley J, Bae K, Choi N, Forster K, Siegel B, Brunetti J, Purdy J, Faria S, Vu T, Choy H. A Phase II Comparative Study of Gross Tumor Volume Definition With or Without PET/CT Fusion in Dosimetric Planning for Non-Small Cell Lung Cancer (NSCLC): Primary Analysis of Radiation Therapy Oncology Group (RTOG) 0515. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 4.

[http://www.redjournal.org/article/S0360-3016\(09\)01074-8/fulltext](http://www.redjournal.org/article/S0360-3016(09)01074-8/fulltext)

Protocol(s): RTOG-0515

Bradley J, Graham M, Bae K, Byhardt R, Govindan R, Fowler J, Purdy J, Michalski J, Gore E, Choy H. Initial Primary Analysis of Phase II for RTOG 0117: A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy and Concurrent Chemotherapy for Patients with Inoperable, Non-Small Cell Lung Cancer (NSCLC). *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. B5.2.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): RTOG-0117

Gore E, Bae K, Langer C, Extermann M, Movsas B, Okunieff P, Videtic G, Choy H. Phase I/II Trial of a COX-2 Inhibitor with Limited Field Radiation for Intermediate Prognosis Patients with Locally Advanced Non-Small Cell Lung Cancer: Radiation Therapy Oncology Group (RTOG) 0213. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. P3.016.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): RTOG-0213

Grosshans D, Bae K, Blumenschein G, Curran W, Robert F, Fossella F, Werner-Wasik M, Doescher P, Choy H, Komaki R. Correlation of Pulmonary and Cardiac Dose Volume Histogram (DVH) Data With the Development of Radiation Adverse Events Following Chemoradiation: Secondary Analysis of Radiation Therapy Oncology Group (RTOG) 0324. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 1080.

[http://www.redjournal.org/article/S0360-3016\(09\)01420-5/fulltext](http://www.redjournal.org/article/S0360-3016(09)01420-5/fulltext)

Protocol(s): RTOG-0324

Harrison A, Anamalayil S, Timmerman R, Straube W, Bosch W, Michalski J, Galvin J, Xiao Y. A Feasibility Study and Optimization of Dosimetric Objective with Heterogeneity Corrections for RTOG Studies with Hypo-fractionated Stereotactic Radiotherapy of Lung Cancers. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 3118.

[http://www.redjournal.org/article/S0360-3016\(09\)02602-9/fulltext](http://www.redjournal.org/article/S0360-3016(09)02602-9/fulltext)

Protocol(s): RTOG-0236

Komaki R, Paulus R, Ettinger D, Videtic G, Bradley J, Glisson B, Choy H. Patterns of First Failure in a Phase II Study of Accelerated High Dose Thoracic Radiation Therapy (TRT) with Concurrent Chemotherapy for Limited Small-cell Lung Cancer (LSCLC): Radiation Therapy Oncology Group (RTOG) 0239. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 72.

[http://www.redjournal.org/article/S0360-3016\(09\)01143-2/fulltext](http://www.redjournal.org/article/S0360-3016(09)01143-2/fulltext)

Protocol(s): RTOG-0239

Komaki R, Paulus R, Ettinger D, Videtic G, Bradley J, Glisson B, Choy H. Normal Tissue Toxicities in a Phase II Study of Accelerated High Dose Thoracic Radiation Therapy (TRT) with Concurrent Chemotherapy for Limited Small Cell Lung Cancer (LSCLC): Radiation Therapy Oncology Group (RTOG) 0239. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. D5.1.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): RTOG-0239

Movsas B, Bae K, Meyers C, Gore E, Bonner J, Sun A, Schild S, Gaspar L, Bogart J, Choy H. Phase III Study of Prophylactic Cranial Irradiation (PCI) versus Observation in Patients with Stage III Non-Small Cell Lung Cancer (NSCLC): Neurocognitive and Quality of Life (QOL) Analysis of RTOG 0214. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 2.

[http://www.redjournal.org/article/S0360-3016\(09\)01072-4/fulltext](http://www.redjournal.org/article/S0360-3016(09)01072-4/fulltext)

Protocol(s): RTOG-0214

Siddiqui F, Langer C, Bae K, Coyne J, Gamerman V, Bryan C, Komaki R, Choy H, Curran W, Watkins-Bruner D, Movsas B. Gender Differences in Survival Among Lung Cancer Patients Treated in Radiation Therapy Oncology Group (RTOG) Trials. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. PD8.3.4.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): RTOG-90-15, RTOG-91-03, RTOG-91-06, RTOG-92-04, RTOG-92-05, RTOG-93-04, RTOG-93-11, RTOG-94-10, RTOG-98-01

Small W, James J, Moore T, Fintel D, Lutz S, Movsas B, Suntharalingam M, Graces Y, Ivker R, Berk L. A Phase II Randomized Trial with Captopril in Patients who have received Radiation Therapy +/- Chemotherapy for Stage II-III B Non-Small Cell Lung Cancer and Stage I Central Non-Small Cell Lung Cancer, or Limited-Stage Small-Cell Lung Cancer: RTOG 0123. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 2622.

[http://www.redjournal.org/article/S0360-3016\(09\)02096-3/fulltext](http://www.redjournal.org/article/S0360-3016(09)02096-3/fulltext)

Protocol(s): RTOG 0123

Sun A, Bae K, Wong S, Bonner J, Schild S, Gaspar L, Bogart J, Werner-Wasik M, Choy H. A phase III comparison of prophylactic cranial irradiation (PCI) versus observation in patients with locally advanced non-small cell lung cancer (LA-NSCLC): initial analysis of primary and secondary endpoints. RTOG 0214. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. C6.6

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): RTOG-0214

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Choy H. Stereotactic Body Radiation Therapy to Treat Medically Inoperable Early-stage Lung Cancer Patients: Analysis of RTOG 0236. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 5.

[http://www.redjournal.org/article/S0360-3016\(09\)01075-X/fulltext](http://www.redjournal.org/article/S0360-3016(09)01075-X/fulltext)

Protocol(s): RTOG-0236

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Choy H. Stereotactic Body Radiation Therapy to Treat Medically Inoperable Early Stage Lung Cancer Patients. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. A4.5.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): RTOG-0236

Watkins Bruner D, Bae K, Siddiqui F, Langer C, Coyne J, Gamerman V, Komaki R, Choy H, Curran W, Movsas B. The Influence of Gender, Race and Marital Status on Survival in Lung Cancer Patients: Meta-Analysis of Radiation Therapy Oncology Group (RTOG) trials. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 1083.

[http://www.redjournal.org/article/S0360-3016\(09\)01423-0/fulltext](http://www.redjournal.org/article/S0360-3016(09)01423-0/fulltext)

Protocol(s): RTOG-90-15, RTOG-91-03, RTOG-91-06, RTOG-92-04, RTOG-92-05, RTOG-93-04, RTOG-93-11, RTOG-94-10, RTOG-98-01

Wolfson A, Bae K, Komaki R, Meyers C, Movsas B, Le Pechoux C, Werner-Wasik M, Videtic G, Garces Y, Choy H. Secondary Endpoints of a Phase II Randomized Trial (RTOG 0212): Impact of Different Total Doses and Schedules of Prophylactic Cranial Irradiation on Chronic Neurotoxicity and Quality of Life for Patients with Limited Disease Small Cell Lung Cancer. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 70.

[http://www.redjournal.org/article/S0360-3016\(09\)01141-9/fulltext](http://www.redjournal.org/article/S0360-3016(09)01141-9/fulltext)

Protocol(s): RTOG-0212

SWOG

Ambrosone CB: Molecular Epidemiology of Lung Cancer. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. M39.1.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): S0424

Chansky K, Mack PC, Crowley J, Lara PN, Hirsch FR: Chemotherapy Outcomes by Histologic Subtype of Non-Small cell Lung Cancer (NSCLC): Analysis of the SWOG Database for Antimicrotubule-Platinum Therapy. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. B2.7.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): S9806, S0003, SWOG-9308

Kim ES, Herbst RS, Moon J, Redman M, Dakhil SR, Hirsch FR, Mack P, Franklin W, Kelly K, Gandara D: S0536: Carboplatin, Paclitaxel, Cetuximab and Bevacizumab Followed by Cetuximab and Bevacizumab Maintenance in Advanced Non-Small Cell Lung Cancer (NSCLC), a SWOG Phase II Study. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. PD3.5.5.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): S0536

Kraut MJ, Moon J, Thomas CR, Sonett J, Jett J, Rusch V, Lyss AP, Gillenwater H, Laurie S, Gandara D: Docetaxel is Not Feasible as Consolidation Therapy after Cisplatin/Etoposide/Concurrent Radiotherapy Followed by Surgical Resection for Pancoast Tumors: Preliminary Results of SWOG 0220. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. PD8.2.6.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): S0220

Other Participating Group(s): ACOSOG, CALGB, ECOG, NCCTG, NCIC Clinical Trials Group

Lara PN, Chansky K, Shibata T, Fukuda H, Tamura T, Saijo J, Lenz H-J, Natale R, Crowley J, Redman M, Gandara DR: Final Pooled Comparative Outcomes Analysis of JCOG 9511 and SWOG 0124, Phase III Trials of Cisplatin + Irinotecan vs. Cisplatin + Etoposide in Extensive Stage Small Cell Lung Cancer. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. D6.1.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): S0124

Mack PC: Role of EGFR Pathway Activation in Never Smoking Patients with Lung Cancer. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. M39.3.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): S0424

Pisters KM, Vallieres E, Bunn P, Crowley J, Chansky K, Gandara D: S9900 Trial Update, Mature Analysis. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. E9.3.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): S9900

Other Participating Group(s): ACOSOG, ECOG, NCCTG, NCIC Clinical Trials Group, RTOG

Santella RM, Zhang Y-J, Wang Q, Redman M, Chansky K, Reid M, Davis W, Gandara D, Powell CA, Albain K, Ambrosone C: Biomarkers of Polycyclic Aromatic Hydrocarbon-DNA Damage and Cigarette Smoke Exposure. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1): Abst. M39.2.

<http://journals.lww.com/jto/toc/2009/09001>

Protocol(s): S0424

Sarcoma/Bone and Soft Tissue Cancers

COG

Calaminus G, Nagarajan R, Hjorth L, Jenney ME, De Vos P, Wiener A: Quality of Life (QOL) Assessment of Patients Undergoing Therapy for Osteosarcoma in the EUROPEAN AMERICAN OSTEOSARCOMA STUDY (EURAMOS). *Pediatr Blood Cancer* 2009; 53(5): Abst. PD.035.

<http://www3.interscience.wiley.com/journal/122588312/abstract>

Protocol(s): AOST0331

Nagarajan R, Wiener A, Calaminus G: Quality of Life (QOL) Assessment of Patients Undergoing Therapy for Osteosarcoma in the EUROPEAN AMERICAN OSTEOSARCOMA STUDY (EURAMOS): Feasibility. *Pediatr Blood Cancer* 2009; 53(5): Abst. PD.014.

<http://www3.interscience.wiley.com/journal/122588312/abstract>

Protocol(s): AOST0331

Weigel BJ, Lyden E, Tagen M, Hawkins D, Breitfeld PP, Meyer W, Anderson J, Stewart CF: Pharmacogenomic Association to Gastrointestinal Toxicities in Patients with High Risk Rhabdomyosarcoma treated with Vincristine and Irinotecan. *Connective Tissue Oncology Society*, Miami, FL, Nov, 2009. Poster Discussion #39370.

<http://www.ctos.org/meeting/2009/program.asp>

Protocol(s): ARST0431, ARST0121

Other Cancer

COG

Wagner LM, Perentesis J, Reid JM, Ames MM, Safgren SL, Nelson, Jr. MD, Ingle AM, Blaney S, Adamson P: Phase I Trial of two Schedules of Vincristine, Oral Irinotecan, and Temozolomide (VOIT Regimen) for Children with Refractory Solid Tumors: a Children's Oncology Group Phase I Consortium Study. *Connective Tissue Oncology Society*, Miami, FL, Nov, 2009. Poster Discussion #39349.

<http://www.ctos.org/meeting/2009/program.asp>

Protocol(s): ADVL0414

NCCTG

Liu H, Sloan J, Sargent D, Satele D, Schaefer P, Halyard M, Grothey A, Garces Y, Brown P, Buckner J: Assessing Simple Measures of Patient-Reported (PR) Fatigue for Oncology Clinical Trials: A Pooled Analysis of 3915 Patients. *International Society for Quality of Life Research (ISOQOL)*, New Orleans, LA, Oct, 2009. Abst. 1762.

<http://www.isoqol.org/2009conference/pdf/AbstractsForBooklet2009.pdf>

Protocol(s): Multiple Trials

Sloan J, Liu H, Sargent D, Satele D, Schaefer P, Halyard M, Grothey A, Garces Y, Brown P, Loprinzi C, Buckner J: A Patient-Level Pooled Analysis of the Prognostic Significance of Baseline Fatigue for Overall Survival (OS) Among 3,915 Patients Participating in 43 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) Oncology Clinical Trials. *International Society for Quality of Life Research (ISOQOL)*, New Orleans, LA, Oct, 2009. Abst. 1764.

<http://www.isoqol.org/2009conference/pdf/AbstractsForBooklet2009.pdf>

Protocol(s): Multiple Trials

RTOG

Ulrich CM, James J, Grady C, Byron C, Hanlon A, Watkins-Bruner D, Curran W. Factors Associated with Attrition in RTOG Clinical Trials. *Int J Radiat Oncol Biol Phys* 2009; 75(3, Supplement): Abst. 190.

[http://www.redjournal.org/article/S0360-3016\(09\)01263-2/fulltext](http://www.redjournal.org/article/S0360-3016(09)01263-2/fulltext)

Protocol(s): Multiple Trials, RTOG 0123

SWOG

Bantum EO, Cheng I, Cassel K, Ka'opua LS, Berenberg J: Cancer prevention clinical trials: Assessing for disparities in recruitment in Hawaii. *Frontiers in Cancer Prevention Research*, Houston, TX, Dec, 2009. Abst. B26.

http://www.aacr.org/Uploads/DocumentRepository/2009_conf/CPR/cpr09_abstracts_poster_b.pdf

Protocol(s): SWOG-9217

Other Participating Group(s): CALGB, ECOG, NCCTG

NCI/CTEP Abstracts & Activities

Abstracts with DCTD and DCP Investigators

Molina JR, Adjei AA, Foster NR, Schild SE, Wright J: NCCTG Phase II Trial (N0621) of the SRC Inhibitor AZD0530 After 4 Cycles of Cytoreductive Chemotherapy for Patients with Extensive Stage Small Cell Lung Cancer (ED-SCLC). *Journal of Thoracic Oncology* 2009; 4(9; suppl 1):Abst. PD4.3.4. <http://journals.lww.com/jto/toc/2009/09001>

Molina JR, Mandrekar SJ, Allen-Ziegler K, Soori GS, Rowland KM, Schild SE, Ivy P, Adjei AA: A Phase II Study of the VEGFR Inhibitor Pazopanib (P) in Patients with Newly Diagnosed or Relapsed Malignant Pleural Mesothelioma (MPM): An NCCTG study. *Journal of Thoracic Oncology* 2009; 4(9; suppl 1):Abst. PD4.1.2. <http://journals.lww.com/jto/toc/2009/09001>

Perez EA, Suman VJ, Davidson NE, Gralow J, Kaufman PA, Ingle JN, Dakhil SR, Zujewski JA, Pisansky TM, Jenkins RB: Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec, 2009. Abst. 80. http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_992332&terms=

Disclaimer: *References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References will appear under only one disease heading chosen as the primary disease but will appear under as many Cooperative Group subheadings as is applicable. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may also be included upon agreement and provided the required information is available. Links to online abstracts have been provided where they were available at the time of publication but there is no guarantee that these links will remain active.*